DOCSLIB.ORG

Abstract Book 2016 Abstracts Begin on Page

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

JOURNAL OF PSYCHOPHARMACOLOGY SUPPLEMENT TO VOLUME 30, ISSUE 8, AUGUST 2016 These papers were presented at the Summer Meeting of the BRITISH ASSOCIATION FOR PSYCHOPHARMACOLOGY 17 – 20 July, Brighton, UK Indemnity The scientific material presented at this meeting reflects the opinions of the contributing authors and speakers. The British Association for Psychopharmacology accepts no responsibility for the contents of the verbal or any published proceedings of this meeting. All contributors completed a Declaration of Interests form when submitting their abstract BAP Office 36 Cambridge Place Hills Road Cambridge CB2 1NS www.bap.org.uk Aii CONTENTS Abstract Book 2016 Abstracts begin on page: SYMPOSIUM 1 New paradigms and treatment approaches in schizophrenia (S01–S04) A1 SYMPOSIUM 2 New perspectives on functions of 5-HT sub-systems (S05–S08) A3 SYMPOSIUM 3 Towards a gender specific psychopharmacology: The impact of neurosteroids, gonadal steroids and oxytocin (S09–S12) A5 SYMPOSIUM 4 Bipolar disorder: Progress on many fronts (S13–S16) A7 SYMPOSIUM 5 Ketamine and addiction: Promising treatment or probable cause? (S17–S20) A9 SYMPOSIUM 6 Neuronal stem cells in mental health: Will neurogenesis and iPS cells give us the antidepressants of the future? (S21–S24) A11 SYMPOSIUM 7 Anhedonia, apathy, amotivation, anergia? Disrupted reward processing as a trans-diagnostic construct in mental illness (S25–S28) A13 SYMPOSIUM 8 Dysfunctional neuro-immune system interactions in psychiatric disorders and their relevance for novel treatment strategies (S29–S32) A15 SYMPOSIUM 9 Innovation in the treatment of obesity and binge eating (S33–S36) A18 CONTENTS Aiii POSTERS Group A: Schizophrenia/Psychosis (A01–A35) A20 Group B: Substance Use (B01–B31) A43 Group C: Affective Disorders (C01–C52) A64 Group D: Anxiety (D01–D11) A99 Group E: Developmental Disorders and Neurodegeneration (E01–E09) A106 Group F: Cognition (F01–F07) A111 Group G: Eating Disorders (G01–G04) A116 Group H: Sleep/Circadian Rhythms (H01–H04) A119 GUEST LECTURE Parsing the serotonin system into distinct functional units (GL1) A122 POSTDOCTORAL SYMPOSIUM Translational models and biomarkers for neuropsychiatric disorders (PD01–PD04) A122 SHORT ORAL PRESENTATIONS Short Orals 1: Substance Use: Neural and behavioural effects See abstracts B09, B11, B16, B24 Short Orals 2: Analysing Anhedonia: From mechanism to treatment See abstracts C12, C15, C30, C46 Short Orals 3: Neurochemical mechanisms of psychosis See abstracts A02, A03, A17, A21 2016 PSYCHOPHARMACOLOGY AWARDS (PW1–PW4) A125 ABSTRACTS A1 S01 PET IMAGING STUDIES OF MICROGLIA, A MARKER FOR NEUROINFLAMMATION IN SCHIZOPHRENIA PATIENTS: POTENTIAL AVENUES FOR NEW TREATMENT APPROACHES Talbot PS, Wolfson Molecular Imaging Centre, Univ of Manchester, 27 Palatine Road, Withington, Manchester M20 3LJ [email protected] Introduction: Positron emission tomography (PET) imaging of the 18kDa translocator protein (TSPO) has been used to investigate whether microglial activation, an indication of neuroinflammation, is evident in the brain of adults with schizophrenia. To date the results have been mixed, with early studies finding evidence for microglial activation and the majority of more recent studies refuting this. The discrepant findings may reflect differences in methodology, radiotracers, and aspects of the patient populations including severity and duration of illness. However, importantly, all of the schizophrenia patients in these previous PET studies were taking antipsychotic medication at the time of scanning, introducing a potential confound due to modulatory effects of antipsychotic medication on microglial activity. We have therefore compared TSPO availability between antipsychotic-free patients with schizophrenia, medicated patients, and matched healthy controls. Methods: we used [11C](R)-PK11195 PET to compare TSPO availability in a predominantly antipsychotic-naïve group of moderate-to-severely symptomatic unmedicated patients (n=8), similarly symptomatic medicated patients with schizophrenia taking risperidone or paliperidone by regular intramuscular injection (n=8), and healthy comparison subjects (n=16). Binding potential (BPND) was calculated using a grey matter cerebellum reference input function and the simplified reference tissue model. Results: we found no evidence for increased TSPO availability in antipsychotic- free patients compared to healthy controls (mean difference 4%, p=0.981). However, TSPO availability was significantly elevated in medicated patients (mean increase 88%, p=0.032) across dorsolateral prefrontal, ventrolateral prefrontal, orbitofrontal, anterior cingulate and parietal cortical regions. In the patients with schizophrenia, TSPO availability was also strongly correlated with negative symptoms measured using the Positive and Negative Syndrome Scale across all the brain regions investigated (r=0.651–0.741). Conclusions: we conclude that the pathophysiology of schizophrenia is not associated with microglial activation in the 2–6 year period following diagnosis, but that antipsychotic treatment with risperidone or paliperidone may induce microglial activation. It remains to be determined whether this activation represents a pro- or anti-inflammatory state, its association with primary negative symptoms and treatment resistance, and whether there are significant differences between antipsychotics. Implications for novel treatment strategies will be discussed. S02 EVIDENCE THAT PARVALBUMIN PATHOLOGY IN SCHIZOPHRENIA CAN BE RESCUED BY NOVEL DRUG TARGETS Harte MK, Manchester Pharmacy School, Univ of Manchester, Stopford Building, Oxford Road, Manchester M13 9PL [email protected] Cognitive deficits remain an unmet clinical need in a number of neuropsychiatric and neurodegenerative disorders. With an improved understanding of the pathology related to these deficits comes the hope of novel treatment strategies. Current evidence from both clinical and preclinical studies suggests a strong involvement of GABAergic interneurons (particularly the parvalbumin (PV) subset) in regulating cognitive function in vivo. Alongside this are numerous reports of dysfunction of these GABAergic neurons in schizophrenia (Lewis et al., Trends Neurosci. 2012; 35(1): 57–67), with a number of relevant preclinical models recapitulating this deficit (e.g. sub-chronic phencyclidine model (Neill et al., 2010; 128(3):419–32)). This emerging understanding of the pathophysiology of schizophrenia offers us the potential to identify novel drug targets through which it may be possible to treat the underlying neural dysfunction and potentially alleviate the cognitive deficits. One such target is the Kv3.1 voltage-gated potassium channel. These channels are expressed on PV interneurons, where they confer the ability of the neurons to fire rapidly and accurately, allowing synchronisation of cortical circuits. A recent post- mortem study found reduction in Kv3.1 protein in un-medicated schizophrenia patients (Yanagi et al. Mol Psychiatry 2014; 19: 573–579). Modulation of this channel may therefore provide a novel target A2 ABSTRACTS for restoration of cognitive function in schizophrenia patients. The presentation will cover data from behavioural, immunohistochemical, electrophysiological and imaging studies in validated preclinical models aimed at investigating the efficacy of this approach for treating cognitive deficits in schizophrenia. Briefly, we demonstrate that treatment (acute and/or chronic) with: - AUT00206, a novel Kv3.1 modulator (Autifony Therapeutics Limited) significantly attenuated the sub-chronic phencyclidine (scPCP) induced social behaviour deficits. - AUT00206 significantly attenuated scPCP induced deficits in different cognitive domains. - AUT00206 significantly enhanced the power of fast network oscillations in the prelimbic cortex from scPCP treated rats. - AUT00206 significantly reversed the scPCP induced PV deficit, an effect dependent on the presence of AUT00206. - AUT00206 significantly reduced ketamine induced BOLD signal changes in cortical and subcortical regions of the rat brain Taken together these results suggest that the modulation of Kv3 channels on PV neurons by AUT00206 could be an important novel approach for improving cognitive deficits and function in schizophrenia patients. Financial Sponsorship: These studies were funded by Innovate UK. S03 UTILITY OF COGNITIVE AND BOLD FMRI BIOMARKERS IN INDIVIDUALS WITH HIGH SCHIZOTYPY TO ASSESS NEW THERAPIES FOR SCHIZOPHRENIA Dourish CT, P1vital, Manor House, Howbery Park, Wallingford, Oxfordshire OX10 8BA [email protected] Schizophrenia is a debilitating, life-long, psychiatric disorder affecting approximately 1% of the world’s population. Antipsychotic drug therapies do not treat all the symptoms of the illness (including positive, negative and cognitive symptoms) and cause significant side-effects including dyskinesia, obesity and diabetes. Therefore, there is a significant unmet need to develop new treatments for schizophrenia that have improved efficacy and fewer side-effects. However, few new compounds have emerged and often promising pre-clinical data have not translated to efficacy in clinical trials. Use of experimental medicine efficacy biomarkers offers a potential way forward for antipsychotic drug development and this presentation reviews a series of recent schizophrenia efficacy biomarker validation studies. Two potential models were examined, an “intermediate phenotype” model and a drug challenge model. The intermediate
Recommended publications
  • Présentation HJ

    Présentation HJ

    Conflits d’intérêts Astra-Zeneca, Janssen, Abacus international, Laboratoire ETAP, Institut Pasteur. Dr Hervé JAVELOT Pharmacien PH Etablissement Public de Santé Alsace Nord Service Pharmacie 141 avenue de Strasbourg 67 170 BRUMATH Tél. : 03 88 64 61 70 Fax : 03 88 64 61 58 Mail : [email protected] Perspectives dans la psychopharmacologie de l’anxiété et de la dépression Hervé JAVELOT Etablissement Public de Santé Alsace Nord Perspectives dans la psychopharmacologie de l’anxiété et de la dépression Traitements des troubles anxio-dépressifs. Les perspectives. ◦ L’axe GABAergique…éternellement prometteur ? ◦ L’incontournable théorie « monoaminergique »… ◦ Des théories alternatives à suivre … Traitements des troubles anxio-dépressifs. Contexte : ◦ XXI ème siècle : Le « siècle de la dépression » s’installe ? (Hardeveld et al., 2010) L’« ère de l’angoisse » s’affirme ? (Auden, 1947) ◦ Prévalence au cours de la vie : 16 à 17% pour la dépression, 17 à 18% pour les troubles anxieux Co-morbidité des 2 troubles dans 20 à 40% des cas (Antony, 2011 ; Depping et al., 2010 ; Hardeveld et al., 2010 ; Huppert, 2009) Auden WH (1947). The Age of Anxiety: A Baroque Eclogue. Random House: New York. Hardeveld F, Spijker J, De Graaf R, Nolen WA, Beekman AT. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand. 2010;122(3):184-91. Antony MM. Recent advances in the treatment of anxiety disorders. Canadian Psychology 2011;52(1), 10-19. Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010;(12):CD008120. Huppert JD. Anxiety disorders and depression comorbidity.
  • Download Complete Issue

    Download Complete Issue

    VOLUME 1, No.2 30 June 2017 ISSN 2514-3174 bsdj.org.uk Advanced Necrotising Enterocolitis How well are we managing them? The British Student Doctor is an open access journal, which means that all content is available without charge to the user or his/her institution. You are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from either the publisher or the author. bsdj.org.uk Journal DOI 10.18573/issn.2514-3174 /thebsdj Issue DOI @thebsdj 10.18573/bsdj.v2i1 @thebsdj This journal is licensed under a Creative Commons Attribution- NonCommercial-NoDerivatives 4.0 International License. The copyright of all articles belongs to The British Student Doctor, and a citation should be made when any article is quoted, used or referred to in another work. The British Student Doctor is an imprint of Cardiff University Press, an innovative open-access publisher of academic research, where ‘open-access’ means free for both readers and writers. cardiffuniversitypress.org Contents EDITORIAL 1 Dr James M Kilgour and Dr Shivali Fulchand Editorial: Mental health and medical students Natalie Ellis, Munzir Quraisy, Dr Matthew Hoskins, ORIGINAL RESEARCH 4 Dr James Walters, Dr Steve Riley and Dr Liz Forty Medical student attitudes to mental health and psychiatry: the use of a patient-experience short film DISCUSSION 12 Alexander J Martin Medicalisation: the definition of disease and the role of tomorrow’s doctors 18 Michael Houssemayne du Boulay An inconsistency
  • A Potential Approach for Treating Pain by Augmenting Glycine-Mediated Spinal Neurotransmission and Blunting Central Nociceptive Signaling

    A Potential Approach for Treating Pain by Augmenting Glycine-Mediated Spinal Neurotransmission and Blunting Central Nociceptive Signaling

    biomolecules Review Inhibition of Glycine Re-Uptake: A Potential Approach for Treating Pain by Augmenting Glycine-Mediated Spinal Neurotransmission and Blunting Central Nociceptive Signaling Christopher L. Cioffi Departments of Basic and Clinical Sciences and Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Albany, NY 12208, USA; christopher.cioffi@acphs.edu; Tel.: +1-518-694-7224 Abstract: Among the myriad of cellular and molecular processes identified as contributing to patho- logical pain, disinhibition of spinal cord nociceptive signaling to higher cortical centers plays a critical role. Importantly, evidence suggests that impaired glycinergic neurotransmission develops in the dorsal horn of the spinal cord in inflammatory and neuropathic pain models and is a key maladaptive mechanism causing mechanical hyperalgesia and allodynia. Thus, it has been hypothesized that pharmacological agents capable of augmenting glycinergic tone within the dorsal horn may be able to blunt or block aberrant nociceptor signaling to the brain and serve as a novel class of analgesics for various pathological pain states. Indeed, drugs that enhance dysfunctional glycinergic transmission, and in particular inhibitors of the glycine transporters (GlyT1 and GlyT2), are generating widespread + − interest as a potential class of novel analgesics. The GlyTs are Na /Cl -dependent transporters of the solute carrier 6 (SLC6) family and it has been proposed that the inhibition of them presents a Citation: Cioffi, C.L. Inhibition of possible mechanism
  • Attention Deficit Hyperactivity Disorder Symptoms

    Attention Deficit Hyperactivity Disorder Symptoms

    SCHRES-07994; No of Pages 6 Schizophrenia Research xxx (2018) xxx–xxx Contents lists available at ScienceDirect Schizophrenia Research journal homepage: www.elsevier.com/locate/schres Attention deficit hyperactivity disorder symptoms as antecedents of later psychotic outcomes in 22q11.2 deletion syndrome Maria Niarchou a,b,⁎, Samuel J.R.A. Chawner a, Ania Fiksinski c,d,e, Jacob A.S. Vorstman d,e,f, Johanna Maeder g, Maude Schneider g, Stephan Eliez g, Marco Armando g, Maria Pontillo h, Stefano Vicari h, Donna M. McDonald-McGinn i, Beverly S. Emanuel i, Elaine H. Zackai i, Carrie E. Bearden j, Vandana Shashi k, Stephen R. Hooper l, Michael J. Owen a, Raquel E. Gur m,n,o, Naomi R. Wray b, Marianne B.M. van den Bree a,1, Anita Thapar a,1, on behalf of the International 22q11.2 Deletion Syndrome Brain and Behavior Consortium a Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, United Kingdom b Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia c Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, the Netherlands d Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada e The Dalglish Family 22q Clinic for 22q11.2 Deletion Syndrome, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada f The Hospital for Sick Children, Toronto, Canada g Department of Psychiatry, University
  • Targeting Glycine Reuptake in Alcohol Seeking and Relapse

    Targeting Glycine Reuptake in Alcohol Seeking and Relapse

    JPET Fast Forward. Published on January 24, 2018 as DOI: 10.1124/jpet.117.244822 This article has not been copyedited and formatted. The final version may differ from this version. TITLE PAGE Targeting Glycine Reuptake in Alcohol Seeking and Relapse Valentina Vengeliene, Martin Roßmanith, Tatiane T. Takahashi, Daniela Alberati, Berthold Behl, Anton Bespalov, Rainer Spanagel Downloaded from The primary laboratory of origin: Institute of Psychopharmacology, Central Institute of jpet.aspetjournals.org Mental Health, Faculty of Medicine Mannheim, Heidelberg University, Germany; at ASPET Journals on September 30, 2021 VV, MR, TTT, RS: Institute of Psychopharmacology, Central Institute of Mental Health, Faculty of Medicine Mannheim, Heidelberg University, Germany; DA: Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center Basel, CH-4070 Basel, Switzerland; BB, AB: Department of Neuroscience Research, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany; AB: Department of Psychopharmacology, Pavlov Medical University, St Petersburg, Russia JPET #244822 JPET Fast Forward. Published on January 24, 2018 as DOI: 10.1124/jpet.117.244822 This article has not been copyedited and formatted. The final version may differ from this version. RUNNING TITLE GlyT1 in Alcohol Seeking and Relapse Corresponding author with complete address: Valentina Vengeliene, Institute of Psychopharmacology, Central Institute of Mental Health (CIMH), J5, 68159 Mannheim, Germany Email: [email protected], phone: +49-621-17036261; fax: +49-621- Downloaded from 17036255 jpet.aspetjournals.org The number of text pages: 33 Number of tables: 0 Number of figures: 6 Number of references: 44 at ASPET Journals on September 30, 2021 Number of words in the Abstract: 153 Number of words in the Introduction: 729 Number of words in the Discussion: 999 A recommended section assignment to guide the listing in the table of content: Drug Discovery and Translational Medicine 2 JPET #244822 JPET Fast Forward.
  • Ocm08458220-1808.Pdf (13.45Mb)

    Ocm08458220-1808.Pdf (13.45Mb)

    1,1>N\1( AACHtVES ** Digitized by the Internet Archive in 2009 with funding from University of Massachusetts, Boston http://www.archive.org/details/pocketalmanackfo1808amer ; HUSETTS ttttter UnitedStates Calendar; For the Year of our LORD 13 8, the Thirty-fecond of American Independence* CONTAINING . Civil, Ecclrfaflirol, Juiicial, and Military Lids in MASSACHUSE i'TS ; Associations, and Corporate Institutions, tor literary, agricultural, .nd amritablt Purpofes. 4 Lift of Post-Towns in Majfacjufetts, with the the o s s , Names of P r-M a ters, Catalogues of the Officers of the GENERAL GOVERNMENT, its With feveral Departments and Eftabiifhments ; Tunes of jhc Sittings ol the feveral Courts ; Governors in each State ; Public Duties, &c. USEFUL TABLES And a Variety of other intereftiljg Articles. * boston : Publiflied by JOHN WEtT, and MANNING & LORING. Sold, wholesale and retail, at their Book -Stores, CornhUl- P*S# ^ytu^r.-^ryiyn^gw tfj§ : — ECLIPSES for 1808. will eclipfes .his THERE befiv* year ; three of the Sun, and two of the Moon, as follows : • I. The firit will be a total eclipfe of the Moon, on Tuefday morning, May io, which, if clear weather, will be viiible as follows : H. M. Commencement of the eclipfe 1 8^ The beginning or total darknefs 2 6 | Mean The middle of the eciiple - 2 53 )> iimc Ending of total darkneis - 3 40 | morning. "Ending of the eclipfe 4 ^8 J The duration of this is eclipfe 3 hours and 30 minutes ; the duration of total darkneis, 1 hour 34 minutes ; and the cbfcunty i8| digits, in the fouthern half of the earth's (hatiow.
  • Treatment of Schizophrenia Course Director: Philip Janicak, M.D

    Treatment of Schizophrenia Course Director: Philip Janicak, M.D

    S6735- Treatment of Schizophrenia Course Director: Philip Janicak, M.D. #APAAM2016 Saturday, May 14, 2016 Marriott Marquis - Marquis Ballroom D psychiatry.org/ annualmeetingS4637 ANNUAL MEETING May 14-18, 2016 • Atlanta Reference • Janicak PG, Marder SR, Tandon R, Goldman M (Eds.). Schizophrenia: Recent Advances in Diagnosis and Treatment. New York, NY: Springer; 2014. Schizophrenia: Recent Diagnostic Advances, Neurobiology, and the Neuropharmacology of Antipsychotic Drug Therapy Rajiv Tandon, MD Professor of Psychiatry University of Florida College of Medicine Gainesville, Florida Annual Meeting of the American Psychiatric Association New York, New York May 3–7, 2014 Disclosure Information MEMBER, WPA PHARMACOPSYCHIATRY SECTION MEMBER, DSM-5 WORKGROUP ON PSYCHOTIC DISORDERS A CLINICIAN AND CLINICAL RESEARCHER Pharmacological Treatment of Any Disease • Know the Disease that you are treating • Nature; Treatment targets; Treatment goals; • Know the Treatments at your disposal • What they do; How they compare; Costs; • Principles of Treatment • Measurement-based; Targeted; Individualized Program Outline • Nature and Definition of psychosis? • Clinical description • What is wrong in psychotic illness • Dimensions of Psychopathology • Neurobiological Abnormalities • Mechanisms underlying antipsychotic effects? • What contributes to Efficacy • Basis of Side-effect differences 5 Challenges in DSM-IV Construct of Psychotic Disorders ♦ Indistinct Boundaries ♦ With Other Disorders (eg., with OCD) ♦ Within Group of Psychotic Disorders (eg. between
  • The Impact of D-Cycloserine and Sarcosine on in Vivo Frontal Neural

    The Impact of D-Cycloserine and Sarcosine on in Vivo Frontal Neural

    Yao et al. BMC Psychiatry (2019) 19:314 https://doi.org/10.1186/s12888-019-2306-1 RESEARCH ARTICLE Open Access The impact of D-cycloserine and sarcosine on in vivo frontal neural activity in a schizophrenia-like model Lulu Yao1, Zongliang Wang1, Di Deng1, Rongzhen Yan1, Jun Ju1 and Qiang Zhou1,2* Abstract Background: N-methyl-D-aspartate receptor (NMDAR) hypofunction has been proposed to underlie the pathogenesis of schizophrenia. Specifically, reduced function of NMDARs leads to altered balance between excitation and inhibition which further drives neural network malfunctions. Clinical studies suggested that NMDAR modulators (glycine, D-serine, D-cycloserine and glycine transporter inhibitors) may be beneficial in treating schizophrenia patients. Preclinical evidence also suggested that these NMDAR modulators may enhance synaptic NMDAR function and synaptic plasticity in brain slices. However, an important issue that has not been addressed is whether these NMDAR modulators modulate neural activity/spiking in vivo. Methods: By using in vivo calcium imaging and single unit recording, we tested the effect of D-cycloserine, sarcosine (glycine transporter 1 inhibitor) and glycine, on schizophrenia-like model mice. Results: In vivo neural activity is significantly higher in the schizophrenia-like model mice, compared to control mice. D-cycloserine and sarcosine showed no significant effect on neural activity in the schizophrenia-like model mice. Glycine induced a large reduction in movement in home cage and reduced in vivo brain activity in control mice which prevented further analysis of its effect in schizophrenia-like model mice. Conclusions: We conclude that there is no significant impact of the tested NMDAR modulators on neural spiking in the schizophrenia-like model mice.
  • Stems for Nonproprietary Drug Names

    Stems for Nonproprietary Drug Names

    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
  • The Irish Catholic Episcopal Corps, 1657 – 1829: a Prosopographical Analysis

    The Irish Catholic Episcopal Corps, 1657 – 1829: a Prosopographical Analysis

    THE IRISH CATHOLIC EPISCOPAL CORPS, 1657 – 1829: A PROSOPOGRAPHICAL ANALYSIS VOLUME 1 OF 2 BY ERIC A. DERR THESIS FOR THE DEGREE OF PHD DEPARTMENT OF HISTORY NATIONAL UNIVERISTY OF IRELAND MAYNOOTH SUPERVISOR OF RESEARCH: DR. THOMAS O’CONNOR NOVEMBER 2013 Abstract This study explores, reconstructs and evaluates the social, political, educational and economic worlds of the Irish Catholic episcopal corps appointed between 1657 and 1829 by creating a prosopographical profile of this episcopal cohort. The central aim of this study is to reconstruct the profile of this episcopate to serve as a context to evaluate the ‘achievements’ of the four episcopal generations that emerged: 1657-1684; 1685- 1766; 1767-1800 and 1801-1829. The first generation of Irish bishops were largely influenced by the complex political and religious situation of Ireland following the Cromwellian wars and Interregnum. This episcopal cohort sought greater engagement with the restored Stuart Court while at the same time solidified their links with continental agencies. With the accession of James II (1685), a new generation of bishops emerged characterised by their loyalty to the Stuart Court and, following his exile and the enactment of new penal legislation, their ability to endure political and economic marginalisation. Through the creation of a prosopographical database, this study has nuanced and reconstructed the historical profile of the Jacobite episcopal corps and has shown that the Irish episcopate under the penal regime was not only relatively well-organised but was well-engaged in reforming the Irish church, albeit with limited resources. By the mid-eighteenth century, the post-Jacobite generation (1767-1800) emerged and were characterised by their re-organisation of the Irish Church, most notably the establishment of a domestic seminary system and the setting up and manning of a national parochial system.
  • Title of the Trial

    Title of the Trial

    RAPIDTFCBT – Draft Protocol V1 - 19 August 2016 TITLE OF THE TRIAL: Pragmatic Randomised controlled trial of a trauma-focused guided self help Programme versus Individual Trauma- Focused Cognitive Behavioural Therapy for post traumatic stress disorder (RAPIDTFCBT) PROTOCOL VERSION NUMBER AND DATE: Version 1.1 – 8 August 2016 SPONSOR: Cardiff University IRAS NUMBER: ISRCTN NUMBER: SPONSOR’S NUMBER: FUNDER’S NUMBER: HTA 14/192/97 This protocol has regard for the HRA guidance and order of content 1 RAPIDTFCBT – Draft Protocol V1 - 19 August 2016 SIGNATURE PAGE The undersigned confirm that the following protocol has been agreed and accepted and that the Chief Investigator agrees to conduct the trial in compliance with the approved protocol and will adhere to the GCP guidelines, the Sponsor’s SOPs, and other regulatory requirements as amended. I agree to ensure that the confidential information contained in this document will not be used for any other purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of the Sponsor I also confirm that I will make the findings of the study publically available through publication or other dissemination tools without any unnecessary delay and that an honest accurate and transparent account of the study will be given; and that any discrepancies from the study as planned in this protocol will be explained. For and on behalf of the Study Sponsor: Signature: ………………………………………………………. Date: ....../....../...... Name (please print): ………………………………………….. Position:
  • 2 2010 June Newsletter 2009 December Newsletter.Qxd

    2 2010 June Newsletter 2009 December Newsletter.Qxd

    June. 2010 Vol. 10 No. 2 This photograph was submitted by member Betty Smith of Mildura marked across the football INSIDE THIS EDITION M.H.S. (Mildura High School or possibly Merbein London Research 2 High School) and dated 1926. Sinking of the Titan 3 We would be interested in putting names to the Accessing 19th Century Vic Police Records 4-5 faces of these players. Nomination form for officebearers 6 Court house visit, Latter Day Saints visit 7 Editor can be contacted on The Tayleur Disaster 8-9 [email protected] Talbot family of Malahide, Ireland 10-12 or drop names into the society rooms. Thomas family reunion 13 Latest library additions 14 Result to March Newsletter Puzzle School photographs 15 Elizabeth Hayden was married to John Stewart Cousins killed in action 16 Victorian Police deaths 17 Society has a new Secretary Murray River lock builders 18-19 New member Naomi Burke has agreed to Research Queries 19 become the new Secretary of the Mildura & District Mildura & District Genealogical Society webpage www.rootsweb.com/~ausmgs/ Genealogical Society. Welcome Naomi. Mildura & District Genealogical Society Inc. P.O. Box 2895 Mildura, Victoria 3502 Email: [email protected] London Research with Eleanor Pugsley of the Genealogical Society of Victoria Inc. London Records rather than in the workhouse infirmary. The registers The many family historians researching ancestors recorded information about the births and baptisms that in London have greeted with great joy the release on occurred at these institutions. Ancestry.co.uk of indexed baptisms, marriages and Poor law generally refers to poor individuals such burials from Church of England parish registers and as the elderly, orphaned, unemployed or sick and Board of Guardian Poor Law records in the greater afflicted.